Data gathered: July 12
AI Stock Analysis - Lexicon Pharmaceuticals (LXRX)
Analysis generated April 24, 2024. Powered by Chat GPT.
Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of breakthrough treatments for human disease. The company has made significant strides in the development of drugs in diabetes, irritable bowel syndrome, and other areas. Their pipeline includes innovative drug candidates that address unmet medical needs, and the company continues to invest in robust research and development.
Stock Alerts - Lexicon Pharmaceuticals (LXRX)
 |
Lexicon Pharmaceuticals | July 10 Price is up by 7.5% in the last 24h. |
|
Lexicon Pharmaceuticals | July 9 Price is up by 7.6% in the last 24h. |
|
Lexicon Pharmaceuticals | July 1 Price is down by -7.5% in the last 24h. |
|
Lexicon Pharmaceuticals | June 30 Price is up by 9.9% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Lexicon Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 16 | Sign up | Sign up | Sign up |
| Patents | 18 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 968 | Sign up | Sign up | Sign up |
| Reddit Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 367 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 13,661 | Sign up | Sign up | Sign up |
| Twitter Followers | 616 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 23 | Sign up | Sign up | Sign up |
| Linkedin Employees | 317 | Sign up | Sign up | Sign up |
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
| Price | $1.08 |
| Target Price | Sign up |
| Volume | 3,260,000 |
| Market Cap | $410M |
| Year Range | $0.29 - $1.3 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Average Rating of “Hold” by AnalystsJuly 10 - ETF Daily News |
 |
While institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownershipJune 29 - Yahoo |
|
HC Wainwright Reaffirms “Buy” Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)June 25 - ETF Daily News |
|
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving Average – Here’s What HappenedJune 24 - ETF Daily News |
|
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of “Hold” from BrokeragesJune 15 - ETF Daily News |
|
Hennion & Walsh Asset Management Inc. Sells 33,201 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)June 9 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 1.3M | 30,000 | 1.2M | -25M | -26M | -0.070 |
| Q4 '24 | 27M | 350,000 | 26M | -34M | -30M | -0.090 |
| Q3 '24 | 1.8M | 71,000 | 1.7M | -65M | -60M | -0.180 |
| Q2 '24 | 1.6M | 170,000 | 1.5M | -53M | -51M | -0.170 |
| Q1 '24 | 1.1M | 180,000 | 960,000 | -48M | -44M | -0.200 |
Insider Transactions View All
| COATS LONNEL filed to buy 914,359 shares at $1.1. November 17 '23 |
| Amouyal Philippe filed to buy 240,332 shares at $1. November 14 '23 |
| COATS LONNEL filed to buy 824,359 shares at $1. November 13 '23 |
| DEBBANE RAYMOND filed to buy 1,340,847 shares at $1. October 12 '23 |
| DEBBANE RAYMOND filed to buy 1,192,027 shares at $1.1. October 12 '23 |
Similar companies
Read more about Lexicon Pharmaceuticals (LXRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Lexicon Pharmaceuticals?
The Market Cap of Lexicon Pharmaceuticals is $410M.
What is the current stock price of Lexicon Pharmaceuticals?
Currently, the price of one share of Lexicon Pharmaceuticals stock is $1.08.
How can I analyze the LXRX stock price chart for investment decisions?
The LXRX stock price chart above provides a comprehensive visual representation of Lexicon Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lexicon Pharmaceuticals shares. Our platform offers an up-to-date LXRX stock price chart, along with technical data analysis and alternative data insights.
Does LXRX offer dividends to its shareholders?
As of our latest update, Lexicon Pharmaceuticals (LXRX) does not offer dividends to its shareholders. Investors interested in Lexicon Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Lexicon Pharmaceuticals?
Some of the similar stocks of Lexicon Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.